作者
Naomi J Patel, Kristin M D'Silva, Tiffany Y‐T Hsu, Michael DiIorio, Xiaoqing Fu, Claire Cook, Lauren Prisco, Lily Martin, Kathleen MM Vanni, Alessandra Zaccardelli, Yuqing Zhang, Jeffrey A Sparks, Zachary S Wallace
发表日期
2022/3
期刊
ACR open rheumatology
卷号
4
期号
3
页码范围
238-246
出版商
Wiley Periodicals, Inc.
简介
Objective
Patients with immune‐mediated diseases treated with anti‐CD20 monoclonal antibodies may have worse coronavirus disease 2019 (COVID‐19) outcomes due to impaired humoral immunity, but differences compared with the general population are unknown.
Methods
We identified patients with immune‐mediated diseases who received anti‐CD20 monoclonal antibodies within 1 year prior to the index date of polymerase chain reaction–confirmed COVID‐19 between January 31, 2020, and January 31, 2021. General population comparators with COVID‐19 were matched up 5:1 by age, sex, and polymerase chain reaction date. Unadjusted and multivariable adjusted (for age, race, body mass index, and Charlson Comorbidity Index) hazard ratios (HRs) and 95% confidence intervals (CIs) for hospitalization, mechanical ventilation, and death in recipients of anti‐CD20 monoclonal antibodies versus …
学术搜索中的文章
NJ Patel, KM D'Silva, TYT Hsu, M DiIorio, X Fu, C Cook… - ACR open rheumatology, 2022